[1] YAO Minwu ZHOU Yongtian,.Clinical Study of Modified Dingxiang Zhuyu Decoction on Refractory Gastroesophageal Reflux Disease of Middle Deficiency and Qi Inversion Type [J]. Modern Traditional Chinese Medicine, 2022, 1(02): 84-89. [doi: 10.13424/j.cnki.mtcm.2022.02.015]
Clinical Study of Modified Dingxiang Zhuyu Decoction on Refractory Gastroesophageal Reflux Disease of Middle Deficiency and Qi Inversion Type
- Article number:
- 1672-0571(2022)02-0084-06
- Keywords:
- Key words：Dingxiang Zhuyudecoction; Middle deficiency Qi inversion type; Refractory gastroesophageal reflux disease
- ZTFLH:
- R571
- Code:
- A
- Abstract:
- Abstract：Objective To observe the clinical efficacy of modified Dingxiang Zhuyu decoction in the treatment of refractory gastroesophageal reflux disease of middle deficiency and Qi inversion type.Methods From May 2020 to January 2021，84 patients with refractory gastroesophageal reflux disease of deficiency Qi inversion type treated in the department of Gastroenterology of Guangdong integrated traditional Chinese and Western medicine hospital were selected as the experimental objects.They were divided into experimental group and control group，with 42 cases in each group.The control group was given oral administration of esomeprazole enteric coated capsule and itopride hydrochloride tablets，and the experimental group was given oral administration of Dingxiang Zhuyu decoction on the basis of the treatment of the control group.The course of treatment of both groups was 4 weeks.The reflux disease questionnaire score，TCM symptom score (epigastric pain，acid reflux，anorexia，loose stool and fullness of epigastric fullness)，endoscopic esophageal mucosal grading score and adverse drug reactions (dizziness，vomiting and rash) were compared between the two groups before and after treatment.Results After treatment，the RDQ score，symptom scores of epigastric pain，acid reflux，anorexia，loose stool，fullness of epigastrium and endoscopic esophageal mucosal grading score in the experimental group decreased (all P<0.05)，while the reflux disease questionnaire score，symptom scores of epigastric pain，anorexia，fullness of epigastrium and endoscopic esophageal mucosal grading score in the control group decreased (all P<0.05)，The scores of the experimental group were better than those of the control group (all P<0.05)，and the adverse reactions of the experimental group were also lower than those of the control group (P<0.05).Conclusion Dingxiang Zhuyu decoction is effective in the treatment of refractory gastroesophageal reflux disease with middle deficiency and Qi inversion，with less adverse reactions.Abstract：Objective To observe the clinical efficacy of modified Dingxiang Zhuyu decoction in the treatment of refractory gastroesophageal reflux disease of middle deficiency and Qi inversion type.Methods From May 2020 to January 2021，84 patients with refractory gastroesophageal reflux disease of deficiency Qi inversion type treated in the department of Gastroenterology of Guangdong integrated traditional Chinese and Western medicine hospital were selected as the experimental objects.They were divided into experimental group and control group，with 42 cases in each group.The control group was given oral administration of esomeprazole enteric coated capsule and itopride hydrochloride tablets，and the experimental group was given oral administration of Dingxiang Zhuyu decoction on the basis of the treatment of the control group.The course of treatment of both groups was 4 weeks.The reflux disease questionnaire score，TCM symptom score (epigastric pain，acid reflux，anorexia，loose stool and fullness of epigastric fullness)，endoscopic esophageal mucosal grading score and adverse drug reactions (dizziness，vomiting and rash) were compared between the two groups before and after treatment.Results After treatment，the RDQ score，symptom scores of epigastric pain，acid reflux，anorexia，loose stool，fullness of epigastrium and endoscopic esophageal mucosal grading score in the experimental group decreased (all P<0.05)，while the reflux disease questionnaire score，symptom scores of epigastric pain，anorexia，fullness of epigastrium and endoscopic esophageal mucosal grading score in the control group decreased (all P<0.05)，The scores of the experimental group were better than those of the control group (all P<0.05)，and the adverse reactions of the experimental group were also lower than those of the control group (P<0.05).Conclusion Dingxiang Zhuyu decoction is effective in the treatment of refractory gastroesophageal reflux disease with middle deficiency and Qi inversion，with less adverse reactions.
References:
[1]V.T.Ivashkin,I.V.Maev,A.S.Trukhmano,D.E.Rumyantseva.Modern achievements in the diagnosis and treatment of the refractory gastroesophageal reflux disease[J].Терапевтический архив,2018,90(8):4-12.
[2］Rena Yadlapati,Kelli DeLay.Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease[J].Medical Clinics of North America,2019,103(1):15-17.
[3］2020年中国胃食管反流病专家共识[J].中华消化杂志,2020,40(10):649-663.
[4］雷鸽,刘新群,范筱,等.高分辨率食管测压联合食管24 h pH-阻抗监测对胃食管反流病的诊断意义[J].第三军医大学学报,2020,42(11):1141-1145.
[5］Manterola Carlos,Grande Luis,Bustos Luis,et al.Prevalence of gastroesophageal reflux disease：a population-based cross-sectional study in southern Chile[J].Gastroenterology report,2020,8(4)：286-292.
[6］张声生,朱生樑,王宏伟,等.胃食管反流病中医诊疗专家共识意见(2017)[J].中国中西医结合消化杂志,2017,25(5):321-326.
[7］陈智颖,刘文新,夏欢欢,等.应用芝加哥分类分析难治性胃食管反流病食管动力特点的研究[J].中国实用内科杂志,2020,40(8):671-673.
[8］国家中医药管理局．中药新药临床研究指导原则(试行)[S]．北京:中国医药科技出版社，2002：140-143．
[9］张馨月,姜小艳,刘冬厚，等.舒郁消瘅汤联合西药治疗难治性反流性食管炎合并焦虑抑郁状态疗效观察[J].现代中西医结合杂志,2019,28(10):1036-1040,1075.
[10］唐丽明,宋宁,张桂贤,等.加味旋覆代赭汤对非酸反流所致慢性食管病变大鼠肠化及CDX2、DLK1表达的影响[J].中国中西医结合外科杂志,2020,26(1):2-7.
[11］Kun Wang,Li-Ping Duan,Xiang-Zhu Zeng,et al.Differences in cerebral response to esophageal acid stimuli and psychological anticipation in GERD subtypes -An fMRI study[J].BMC Gastroenterology,2011,11(1):28.
[12］左军,牟景光,胡晓阳.半夏化学成分及现代药理作用研究进展[J].辽宁中医药大学学报,2019,21(9):26-29.
[13］白雯静,姬良亮,王月玲.甘草、黄芪、党参中27种重金属及微量元素含量变化的研究[J].食品安全质量检测学报,2021,12(4):1448-1455.
[14］刘蓬蓬,张凡,史辑,等.UPLC-MS/MS法测定不同温度定向炮制黄芪中8种苷类和4种苷元成分的含量[J].中国药房,2020,31(3):287-293.
[15］高同银,崔同淑,孙国香.浅谈甘草解毒作用[J].河北中医,1994,16(3):46.
[16］潘红波,王衬衬,谢典,等.橘皮素药理作用及其机制研究进展[J].江西科技师范大学学报,2020,19(6):80-84.
[17］闫孟琳,丛龙飞,张子玥,等.基于质量标志物的当归抗炎功效近红外快速评价[J].分析测试学报,2020,39(11):1320-1326.
Memo
基金项目：广东省中医药局科研项目(20201049)